[1]Xingtai Cardiovascular Disease Hospital,,China
[2]Zhejiang University, Department of Cardiology,Hangzhou,China
[3]s Hospital, Department of Cardiology,Xian,China
[4]Second Affiliated Hospital of Harbin Medical University, Department of Cardiology,Harbin,China
[5]s Armed Police Forces, Department of Cardiology,Tianjin,China
[6]Capital Medical University China, Department of Cardiology,Beijing,China
[7]Peking University,Beijing,China
[8]Daqing Oilfield General Hospital,Harbin,China
[9]China Medical University Shenyang, Department of Cardiology,Shenyang,China
[10]The Affiliated DrumTower Hospital of Nanjing University Medical School, Department of Cardiology,Nanjing,China
[11]Shanghai Jiaotong University, Institute of Food and Nutraceutical Science,Shanghai,China
[12]Shanghai Jiaotong University, Department of Cardiology,Shanghai,China
[13]Xinhua Hospital,Shanghai,China
[14]Wuhan University, State Key Laboratory of Virology,Wuhan,China
[15]Hangzhou First People’s Hospital, Department of Cardiology,Hangzhou,China
[16]Nanjing Medical University, Department of Cardiology,Nanjing,China
[17]Xuzhou Central Hospital, Department of Cardiology,Xuzhou,China
[18]Affiliated Hospital of Guangdong Medical University, Cardiovascular Medicine Center,Zhanjiang,China
[19]Guangdong Medical University, Department of Cardiology,Zhanjiang,China
[20]Weifang Yidu Zhongxin Hospital,,China
[21]Shandong University, Faculty of Science,Jinan,China
[22]Second Affiliated Hospital of Preclinical Medicine College of Kunming Medical University, Department of Cardiology,Kunming,China
[23]Huazhong University of Science and Technology, Department of Internal Medicine and Genetic Diagnosis Center,Wuhan,China
[24]Hubei General Hospital, Department of Cardiology,Wuhan,China
[25]Xiangfan City Central Hospital,,China
[26]Fudan University, Department of Radiation Protection,Shanghai,China
[27]s Hospital of Yulin City,,China
[28]Beijing Luhe Hospital,Beijing,China
[29]Harbin Medical University, Key Laboratory of Drug Research,Harbin,China
[30]Zhujiang Hospital,Guangzhou,China
[31]First Affiliated Hospital of Harbin Medical University, Department of Cardiology,Harbin,China
[32]Southeast University, Department of Critical Care Medicine,Nanjing,China
[33]Renji Hospital, Department of Cardiology,Shanghai,China
[34]Ministry of Education China, Key Laboratory of Molecular Cardiovascular Science,Beijing,China
[35]Jiangsu University, Department of Cardiology,Zhenjiang,China
[36]Yantai Yuhuangding Hospital,Yantai,China
[37]Yantai Yuhuangding Hospital, Department of Cardiology,Yantai,China
[38]Shandong University, Department of Cardiology,Jinan,China
[39]Sichuan University, Department of Cardiology,Chengdu,China
[40]Huadong Hospital,Shanghai,China
[41]Shandong Provincial Hospital,Jinan,China
[42]Shandong Provincial Hospital, Department of Cardiology,Jinan,China
[43]Kunming Medical College,Kunming,China
[44]Fujian Medical University, Department of Cardiology,Fuzhou,China
[45]Fudan University, Department of Cardiology,Shanghai,China
[46]Fudan University, Shanghai Institute of Cardiovascular Diseases,Shanghai,China
[47]Fuwai Hospital, Department of Cardiology,Beijing,China
[48]
[49]The First Hospital of Harbin, Department of Dermatology,Harbin,China
[50]Tangdu Hospital, Fourth Military Medical University, Department of Cardiology,Xian,China
[51]Tianjin Chest Hospital,Tianjin,China
[52]Tongji University, Department of Cardiology,Shanghai,China
[53]s Hospital, Department of Cardiology,Shenyang,China
[54]Central Hospital, Department of Cardiology,Shanghai,China
[55]Dalian Medical University, Department of Cardiology,Dalian,China
[56]Guangdong General Hospital,Guangzhou,China
[57]s Liberation Army, Department of Cardiology,Beijing,China
[58]Qingdao University, School of Medicine, Department of Cardiology,Qingdao,China
[59]Qingdao University, Department of Cardiology,Qingdao,China
[60]Chengdu Militar General Hospital,,China
[61]s Hospital,,China
[62]an Jiaotong University, Department of Cardiology,Xian,China
[63]s Hospital of Jining City,,China
[64]General Hospital of Fushun Mining Group,,China
[65]Shanxi Provincial Institute of Cardiovascular Disease,,China
[66]Ocean University of China, School of Mathematical Sciences,Qingdao,China
[67]The Second Department of Cangzhou Cardiovascular Institute,,China
[68]Xiangya Hospital of Central-south University, Department of Cardiology,Changsha,China
[69]Changhai Hospital, Department of Cardiology,Shanghai,China
[70]Tianjin First Central Hospital,Tianjin,China
[71]Harbin Medical University, Department of Cardiology,Harbin,China
[72]Shandong University, Department of Ophthalmology,Jinan,China
[73]Xiamen University, Department of Cardiology,Xiamen,China
[74]s Hospital of Ningbo City,,China
[75]Weifang Medical College,Weifang,China
[76]Nan Fang Hospital, Department of Cardiology,Guangzhou,China
[77]Huazhong University of Science and Technology, Laboratory of Cardiovascular Immunology,Wuhan,China
[78]China Medical University Shenyang,Shenyang,China
[79]Dalian 210 Hospital,,China
[80]Chongqing Medical University, Department of Cardiology,Chongqing,China
[81]Mahidol University,Nakon Pathom,Thailand
[82]Bina Waluya Cardiac Hospital,,Indonesia
[83]University of Indonesia - Dr. Cipto Mangunkusumo Hospital, Department of Internal Medicine,Jakarta,Indonesia
Aims: The FOCUS registry is a prospective, multicentre, web-based programme designed to collect clinical outcome data from real-world patients receiving the second-generation cobalt-chromium sirolimus-eluting stent (CoCr-SES). Methods and results: From March 2009 to February 2010, a total of 5,084 patients from 83 centres who were eligible to receive CoCr-SES were enrolled in the FOCUS registry. The primary endpoint was 12-month major adverse cardiac events (MACE, defined as the composite of cardiac death, myocardial infarction [MI], and target vessel revascularisation [TVR]). One-year data were available for 5,013 (98.6%) of the 5,084 patients enrolled. The primary endpoint occurred in 174 (3.47%) of 5,013 patients, consisting of 43 (0.86%) cardiac deaths, 132 (2.63%) MI, and 46 (0.92%) TVR. According to the Academic Research Consortium definition, definite and probable stent thrombosis (ST) occurred in 0.52% (26/5,013) of patients, including 19 cases of early ST and 7 of late ST. The 12-month MACE rates were 3.73% and 2.60% for extended-use and standard-use patients, respectively (p=0.065). Conclusions: The second-generation CoCr-SES was associated with low rates of 12-month MACE and ST in a broad spectrum of patients, thereby confirming the clinical safety and efficacy of this stent in a real-world setting. ? Europa Digital & Publishing 2012. All rights reserved.
(8.0+极速模式)